INTRODUCTION {#s1}
============

Identifying reliable prognostic biomarkers for cancer patients is a longstanding oncology research goal. To date, the majority of cancer prognosis biomarker findings have focused on cancer cell centric biomarkers, such as cancer cell gene mutations, miRNA and lncRNA secretions, and relative progression protein expressions \[[@R1]--[@R5]\]. However, cancer evolution is also greatly influenced by the immune system and complex milieu, indicating that biomarker research should also consider the impact of factors originating from outside of the tumor cells \[[@R6]\].

The MHC class I chain related-protein A (MICA) and B (MICB) are cancer cell-surface molecules that reflect both cancer cell-centric biological behavior and host immune status. The major histocompatibility complex (MHC) class I chain related (MIC) gene family, which lies within the HLA region, consists of five members: MICA, MICB, MICC, MICD, and MICE. Of these five members, MICA and MICB are the only functional genes \[[@R7]--[@R9]\], which are frequently expressed by carcinomas of the breast, lung, colon, ovary, kidney, prostate, as well as in melanomas, gliomas, and leukemia \[[@R10], [@R11]\]. MICA and MICB, as signals of cellular stress, engage with natural killer group 2D (NKG2D). This engagement actives the cytolytic responses of γδ T cells and NK cells against epithelial tumor cells \[[@R12]\].

In addition to the membrane-bound form, a soluble isoform of MICA/B (sMICA/B) is present in the serum. This serum-soluble form is derived from the proteolytic shedding of the membrane bound molecule. MICA present on the surface forms a complex with a disulfide isomerase/chaperone (ERp5). This complex induces a conformational change, enabling proteolytic cleavage of MICA by a disintegrin and metalloproteinase (ADAM) proteins \[[@R13]\]. Then, the interaction of sMICA/B with NKG2D results in the endocytosis and degradation of receptor-ligand complexes and also suppresses NKG2D-mediated host cancer rejection \[[@R14], [@R15]\]. Therefore, MICA/B and sMICA/B, reflecting the cancer cell centric biological behavior and tumor immune surveillance status, could be a potential prognostic biomarker of cancer patients.

Indeed, this correlation between expression of MICA/B and survival has been reported in a wide range of human carcinomas, including colorectal-, hepatocellular-, pancreatic-, gastric-, and lung carcinoma as well as melanoma \[[@R16]--[@R22]\]. However, some studies also report that high MICA/B expression is associated with unfavorable outcomes in ovarian cancer, non-small cell lung carcinoma, and breast cancer \[[@R23]\]. Previous studies have been carried out across many types of cancer, with widely different sample sizes and outcomes. It is still ambiguous whether the prognostic potential of MICA/B is attributable to the biologic properties of a specific cancer type, whether the prognosis value of MICA/B relies on their soluble isoform, and whether their prognosis effect depends on methodology differences.

Based on current knowledge, low level of sMICA/B in serum and high expression of MICA/B are expected to be associated with less immune escape and stronger cytolytic ability of effector cells, respectively\[[@R24]--[@R26]\]. And serum soluble MICA/B and cancer cell-surface MICA/B are detected by two different methods. At the same time, these up- or down- regulated molecules on cancer cell surface or in patient serum are all associated with patients' survival. Therefore, we conducted a systematic review and two meta-analysises to establish pooled estimates for survival outcomes based on sMICA/B serum levels and MICA/B cell surface expression in different types of cancers.

RESULTS {#s2}
=======

A total of 2,588 patients were included in the analysis, with the sample sizes ranging from 48 to 222 between the included studies, and the published years between 2007 and 2016. Of 171 citations, we identified 19 articles (Figure [1](#F1){ref-type="fig"}) encompassing 10 different cancer types that met the inclusion criteria, including cervical cancer, ovarian cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer, hepatocellular carcinoma, oral squamous cell carcinoma(OSCC), lung carcinoma, melanoma, and multiple myeloma (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Studies of soluble MICA/B comprised a total of 1,482 patients with 7 different types of carcinoma: non-small cell lung, cervical, pancreatic, oral squamous cell, hepatocellular carcinoma, melanoma, and multiple myeloma \[[@R27]--[@R32]\]. The largest number of studies focused on melanoma (5 studies, 628 patients). In the 10 immunohistochemistry (IHC) studies, we included 1,183 patients with 7 different types of carcinoma: non-small cell lung, cervical, ovarian, gastric, cholangiocarcinoma, pancreatic, and hepatocellular carcinoma \[[@R17], [@R19], [@R27], [@R33], [@R34]\]. The largest number of studies focused on non-small cell lung carcinoma (3 studies, 413 patients). Tissue expression of MICA/B was detected by immunohistochemical staining, and all serum sMICA/B studies were performed using ELISA. The Newcastle-Ottawa scale (NOS) confirmed that most of the studies were of high quality (Table [3](#T3){ref-type="table"}).

![Flow diagram of search strategy and study selection](oncotarget-08-96384-g001){#F1}

###### Baseline characteristics for soluble MICA/B related studies included in meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study           Year of publication   MICA/B   Type of cancer                 Country   No. of patients   Cut off point\   Expression\   Method   Detective system   Median duration of follow up\   HR estimation method   Multivariable analysis   Hazard ratios (95%CI)   *p* value
                                                                                                            (pg/ml)          (High:low)                                (months)                                                                                                
  --------------- --------------------- -------- ------------------------------ --------- ----------------- ---------------- ------------- -------- ------------------ ------------------------------- ---------------------- ------------------------ ----------------------- -----------
  **Wang**        2015                  sMICA    Non-small cell lung cancer     China     207               39.93            156:51        ELISA    Roche              NA                              Reported in the text   Yes                      2.39(1.30-4.98)         0.002

  **Koguchi-1**   2015                  sMICA    Melanoma                       US        124               247              31:93         ELISA    R&D Systems        31                              Reported in the text   Yes                      1.75(1.02-3.01)         0.042

  **Koguchi-2**   2015                  sMICA    Melanoma                       US        123               247              26:97         ELISA    R&D Systems        31                              Reported in the text   Yes                      0.94(0.60-1.47)         0.773

  **Koguchi-3**   2015                  sMICA    Melanoma                       Brazil    48                247              28:21         ELISA    R&D Systems        40                              Reported in the text   Yes                      1.48 (0.67--3.28)       0.328

  **Li**          2013                  sMICA    Hepatocellular carcinoma       China     60                1000             28:32         ELISA    Ancell             32                              Reported in the text   Yes                      1.471(1.11-1.95)        0.008

  **Wu**          2013                  sMICB    Melanoma                       China     125               7.92             64:61         ELISA    R&D Systems        NA                              Data extrapolated      No                       2.78(1.40-5.51)         0.004

  **Kumar-1**     2012                  sMICA    HBV-hepatocellular carcinoma   Japan     111               5                28:83         ELISA    R&D Systems        67.1                            Data extrapolated      No                       3.88(1.18-12.77)        0.026

  **Kumar-2**     2012                  sMICA    HCV-hepatocellular carcinoma   Japan     129               5                44:85         ELISA    R&D Systems        67.1                            Data extrapolated      No                       0.91(0.39-2.09)         0.8241

  **Duan**        2011                  sMICA    Pancreatic cancer              China     77                290              33:44         ELISA    R&D Systems        11.7                            Reported in the text   Yes                      3.96(2.52--7.96)        0.004

  **Tamaki**      2010                  sMICB    Oral squamous cell carcinoma   Japan     60                24               23:37         ELISA    R&D Systems        NA                              Data extrapolated      No                       3.88(0.42-35.84)        0.232

  **Paschen**     2009                  sMICA    Melanoma                       Germany   208               400              NA            ELISA    R&D Systems        38.3                            Data extrapolated      No                       1.62(1.19-2.20)         0.002

  **Tamaki**      2008                  sMICA    Oral squamous cell carcinoma   Japan     113               50               41:72         ELISA    R&D Systems        NA                              Data extrapolated      No                       2.43(0.85-6.94)         0.098

  **Rebmann**     2007                  sMICA    Multiple myeloma               Germany   97                305              59:38         ELISA    IMMATICS           53                              Reported in the text   Yes                      3.44(1.40--8.44)        0.007
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Baseline characteristics for MICA/B related studies included in meta-analysis

  Study            Year of publication   MICA/B   Type of cancer               Country   No. of patients   cut off point   Expression (High:Low)   Method   IHC antibody   Antibody dilution   Median duration of follow up (months)   HR estimation method   Multivariable analysis   Hazard ratios (95%CI)   p value
  ---------------- --------------------- -------- ---------------------------- --------- ----------------- --------------- ----------------------- -------- -------------- ------------------- --------------------------------------- ---------------------- ------------------------ ----------------------- ---------
  **Okita**        2016                  MICA/B   Non-small cell lung cancer   Japan     91                0-1,2-3         28:63                   IHC      Santa Cruz     1:50                41.4                                    Reported in the text   Yes                      0.59(0.20--1.75)        0.342
  **Tsukagoshi**   2016                  MICA/B   Cholangiocarcinoma           Japan     82                0-1,2           67:15                   IHC      Santa Cruz     1:800               16.5                                    Reported in the text   Yes                      0.58(0.29-1.21)         0.139
  **Chen**         2016                  MICA     Gastric cancer               China     95                0-4,5-7         38:57                   IHC      Abcam          NA                  47.4                                    Reported in the text   Yes                      0.64(0.42--0.98)        0.040
  **Zhao**         2016                  MICA/B   Lung adenocarcinoma          China     100               0-4,5           38:62                   IHC      Novus          1:150               14.4                                    Reported in the text   Yes                      3.39(2.04-7.36)         0.001
  **Cho**          2014                  MICA/B   Cervical cancer              Korea     195               0-12            112:83                  IHC      Novus          1:50                169                                     Reported in the text   No                       0.53 (0.20-1.36)        0.189
  **Zhang**        2014                  MICA     Hepatocellular carcinoma     China     143               0-12            64:79                   IHC      Abcam          1:100               24                                      Reported in the text   Yes                      0.91(0.49-1.69)         0.774
  **Fang**         2014                  MICA/B   Hepatocellular carcinoma     China     96                0-12            75:21                   IHC      Abgent         1:100               NA                                      Data extrapolated      No                       0.35(0.16-0.79)         0.009
  **Chen**         2013                  MICA     Non-small cell lung cancer   China     222               0-4,5-7         84:138                  IHC      NA             1:25                13                                      Reported in the text   Yes                      3.08(1.52-6.25)         0.002
  **Duan**         2011                  MICA     Pancreatic cancer            China     77                0-1,2           37:40                   IHC      Santa Cruz     1:100               11.7                                    Reported in the text   Yes                      0.29(0.12-0.72)         0.007
  **Li**           2008                  MICA/B   Ovarian cancer               Japan     82                0-1,2           42:40                   IHC      Biolegend      NA                  68.4                                    Reported in the text   Yes                      1.36(0.54-3.45)         0.513

###### Quality assessment of eligible studies (Newcastle-Ottawa scale)

  Study                 Selection   Comparability   Outcome   Total                   
  --------------------- ----------- --------------- --------- ------- --- --- --- --- ---
  **Okita 2016**        1           1               1         1       1   1   1   1   8
  **Tsukagoshi 2016**   1           1               1         1       1   1   1   1   8
  **Zhao 2016**         1           1               1         1       1   1   1   1   8
  **Chen 2016**         1           1               1         1       1   1   1   1   8
  **Koguchi 2015**      1           1               1         1       1   1   1   1   8
  **Wang 2015**         0           1               1         1       1   0   1   1   6
  **Cho 2014**          1           1               1         1       1   1   1   1   8
  **Fang 2014**         1           1               1         1       1   1   1   0   7
  **Zhang 2014**        1           1               1         1       1   1   1   1   8
  **Chen 2013**         1           1               1         1       1   1   1   1   8
  **Li 2013**           1           1               1         1       1   1   1   1   8
  **Wu 2013**           1           1               1         1       1   1   1   0   7
  **Kumar 2012**        1           1               1         0       1   1   1   1   7
  **Duan 2011**         0           1               1         1       1   1   1   0   6
  **Tamaki 2010**       1           1               1         1       1   1   1   0   7
  **Paschen 2009**      1           1               1         1       1   1   1   1   8
  **Tamaki 2008**       1           1               1         1       1   1   1   0   7
  **Li 2008**           1           1               1         1       1   1   1   0   7
  **Rebmann 2007**      1           1               1         1       1   1   1   1   8

Prognostic effect of serum sMICA/B on OS in various cancer types {#s2_1}
----------------------------------------------------------------

Thirteen studies comprising 1,482 patients indicated a correlation between serum sMICA/B and OS. Meta-analysis of all these studies revealed a significant association between serum sMICA/B and survival, with higher sMICA/B in serum associated with a significantly lower OS rate, with a pooled HR of 1.65 (95% CI \[1.42--1.92\], *P* \< 0.00001). The fixed-effects model was adopted to verify the significance of heterogeneity (I^2^ = 45%, *P* = 0.04; Figure [2](#F2){ref-type="fig"}). Subgroup analyses were performed to evaluate the effects of various clinical variables on pooled OS (Table [4](#T4){ref-type="table"}).

![Forest plot for the association between soluble MICA/B levels with prognosis](oncotarget-08-96384-g002){#F2}

###### Subgroup analysis of the prognostic significance of soluble MICA/B

                                  Number of studies   Number of patients   HR 95%CI            Overall effect*P*-value   Subgroup differences *P*-value   *I*^2^
  ------------------------------- ------------------- -------------------- ------------------- ------------------------- -------------------------------- --------
  **Cancer type**                                                                                                        0.47                             
  ** Melanoma**                   5                   628                  1.52 (1.23--1.88)   \< 0.0001                                                  49%
  ** OSCC**                       2                   173                  2.65 (1.02--6.84)   0.04                                                       0%
  ** Digestive system cancers**   5                   377                  1.70 (1.35--2.13)   \< 0.00001                                                 58%
  **ELISA**                                                                                                              0.09                             
  ** sMICA**                      11                  1297                 1.60 (1.37--1.87)   \< 0.00001                                                 47%
  ** sMICB**                      2                   185                  2.86 (1.49--5.51)   0.002                                                      0%
  **Multivariate correction**                                                                                            0.48                             
  ** Yes**                        7                   736                  1.59 (1.32--1.92)   \< 0.00001                                                 58%
  ** No**                         6                   746                  1.78 (1.38--2.28)   \< 0.00001                                                 28%
  **Sample size**                 5                                                                                      0.79                             
  ** ≤ 100**                      5                   342                  1.70 (1.33--2.17)   \< 0.0001                                                  44%
  ** \> 100**                     8                   1140                 1.63 (1.34--1.97)   \< 0.00001                                                 52%

Subgroup analysis of the prognostic effect of sMICA/B in different cancer subtypes {#s2_2}
----------------------------------------------------------------------------------

Subgroup analyses and funnel plot of bias were implemented according to cancer type. According to our current included studies, we divided the cancer into three subtypes: digestive system cancers (hepatocellular carcinoma and pancreatic cancer), melanoma, and OSCC. Another two studies in multiple myeloma and non-small cell lung carcinoma were excluded in this subgroup analysis. High sMICA and sMICB levels were associated with significantly longer OS in various cancer types, including melanoma (HR = 1.52, 95% CI \[1.23--1.88\], *P \<* 0.0001), OSCC (HR = 2.65, 95% CI \[1.02--6.84\], *P* = 0.04), and digestive system cancers (HR = 1.70, 95% CI \[1.35--2.13\], *P \<* 0.00001; [Supplementary Figure 1A, 1B](#SD1){ref-type="supplementary-material"}).

Subgroup analysis according to sMICA level and sMICB level {#s2_3}
----------------------------------------------------------

Significant differences were found between the high level and low level of sMICA/B for cancer patient survival prognosis. For sMICA, the result showed that the pooled HR = 1.60, 95% CI \[1.37--1.87\], *P* \< 0.00001, with a heterogeneity analysis of I^2^ = 47%, *P* = 0.04. For sMICB, HR = 2.86, 95% CI \[1.49--5.51\], *P* = 0.002 with heterogeneity analysis I^2^ = 0%, *P* = 0.78 ([Supplementary Figure 2A, 2B](#SD1){ref-type="supplementary-material"}). These results suggested that, compared with sMICA, sMICB is a more reliable prognostic marker for patients with cancer.

Subgroup analysis according to multivariate correction and sample size {#s2_4}
----------------------------------------------------------------------

The association between sMICA/B and OS was significant in studies with multivariate correction (HR = 1.59, 95% CI \[1.32--1.92\], *P* \< 0.00001) or univariate analysis (HR = 1.78, 95% CI \[1.38--2.28\], *P* \< 0.00001; ([Supplementary Figure 3A, 3B](#SD1){ref-type="supplementary-material"}). The association between sMICA/B and OS was significant in studies with sample sizes both less than or equal to 100 (HR = 1.70, 95% CI \[1.33--2.17\], *P* \< 0.0001) and more than 100 (HR = 1.63, 95% CI \[1.34--1.97\], *P* \< 0.00001; [Supplementary Figure 4A, 4B](#SD1){ref-type="supplementary-material"}).

The prognostic effect of MICA/B expression on OS in various cancer types {#s2_5}
------------------------------------------------------------------------

OS was reported in 10 studies of MICA/B expression in a total of 1,183 cancer patients. The meta-analysis of all these studies revealed a significant association between MICA/B expression and OS. No statistically significant association was observed between high MICA/B expression and longer OS (HR = 0.85, (95% CI \[0.49--1.48\], *P* = 0.58). The random-effects model was adopted to determine the significance of heterogeneity (I^2^ = 84%, *P* \< 0.00001; Figure [3](#F3){ref-type="fig"}).

![Forest plot for the association between MICA/B expression levels with prognosis](oncotarget-08-96384-g003){#F3}

Subgroup analysis of the prognostic effect of MICA/B expression in different cancer subtypes {#s2_6}
--------------------------------------------------------------------------------------------

Table [5](#T5){ref-type="table"} shows the results of meta-analyses of OS for each subgroup analysis. We divided the cancer types into 3 categories: digestive system cancer (including:cholangiocarcinoma, gastric cancer, hepatocellular carcinoma, pancreatic cancer), respiration system cancer (including:lung adenocarcinoma, and non-small cell lung carcinoma), and gynecologic malignant tumors (including: ovarian cancer and cervical cancer). High MICA expression was associated with significantly longer OS in cancers of the digestive system (HR = 0.56, 95% CI \[0.39--0.80\], *P* = 0.002; I^2^ = 35%), non-small cell lung carcinoma (HR = 2.06, 95% CI \[0.86--4.94\], *P* = 0.10; I^2^ = 76%), and gynecologic malignant tumors (HR = 0.85, 95% CI \[0.34--2.15\], *P* = 0.74; I^2^ = 49%). There was a significant difference between subgroups by cancer types (*P* = 0.02, I^2^ = 73.5%). These results suggested that the prognostic effect of MICA/B expression for cancers of the digestive system was more powerful than that for the other cancer types. MICA/B expression level may not be a useful prognostic indicator in gynecologic malignant tumors and non-small cell lung carcinoma ([Supplementary Figure 5A, 5B](#SD1){ref-type="supplementary-material"}).

###### Subgroup analysis of the prognostic significance of MICA/B

                                   Number of studies   Number of patients   HR 95%CI            Overall effect *P*-value   Subgroup difference *p* value   *I*^2^
  -------------------------------- ------------------- -------------------- ------------------- -------------------------- ------------------------------- --------
  **Cancer type**                                                                                                          0.02                            
  **Respiratory system cancers**   3                   413                  2.06 (0.86--4.94)   0.10                                                       76%
  **Digestive system cancers**     5                   493                  0.56 (0.39--0.80)   0.002                                                      35%
  **Gynecologic cancers**          2                   277                  0.85 (0.34--2.15)   0.74                                                       49%
  **Multivariate correction**                                                                                              0.04                            
  **Yes**                          8                   892                  1.01 (0.54--1.86)   0.99                                                       85%
  **No**                           2                   291                  0.41 (0.23--0.76)   0.004                                                      0%
  **Antibody**                                                                                                             0.95                            
  **MICA**                         4                   537                  0.87 (0.38--1.96)   0.73                                                       85%
  **MICA/B**                       6                   646                  0.84 (0.36--1.93)   0.68                                                       85%
  **Sample size**                                                                                                          0.45                            
  **≤ 100**                        7                   623                  0.74 (0.37--1.50)   0.41                                                       86%
  **\> 100**                       3                   560                  1.18 (0.44--3.15)   0.74                                                       80%

Subgroup analysis according to MICA or MICA/B expression {#s2_7}
--------------------------------------------------------

Among the 10 studies, 6 of them reported detection of MICA and MICB together, while 4 reported the detection of MICA only. High MICA/B expression was not significantly associated with longer OS (HR = 0.84, 95% CI \[0.36--1.93\], *P* = 0.68), and the pooled results from MICA did not reveal a significant association with OS (HR = 0.87, 95% CI \[0.38--1.96\], *P* = 0.73; [Supplementary Figure 6A, 6B](#SD1){ref-type="supplementary-material"}).

Subgroup analysis according to multivariate correction and sample size {#s2_8}
----------------------------------------------------------------------

We next investigated whether heterogeneity resulted from the difference in statistical methods used between studies. The results of multivariate adjusted analysis for OS were reported in 8 studies; however, in the other 2 studies, 1 study was data extrapolated and 1 was from a univariate analysis. High MICA expression was associated with significantly longer OS in the univariate analysis subgroup (HR = 0.41, 95% CI \[0.23--0.76\], *P* = 0.004). However, there was no statistically significant effect observed in the multivariate analysis subgroup (HR = 1.01, 95% CI \[0.54--1.86\], *P* = 0.99). This result indicated that multivariate analysis or univariate analysis did not represent the major sources of heterogeneity ([Supplementary Figure 7A, 7B](#SD1){ref-type="supplementary-material"}). We further divided the 10 studies based on large sample size (*n* \> 100) or small sample size (n ≤ 100). Subgroup analysis indicated no statistically significant association between MICA/B and survival for either the subgroup with the small sample size (HR = 0.74, 95% CI \[0.37--1.50\], *P* = 0.41) or that with the large sample size (HR = 1.18, 95% CI \[0.44--3.15\], *P* = 0.74). These results indicated that heterogeneity were not from sample size ([Supplementary Figure 8A, 8B](#SD1){ref-type="supplementary-material"}).

Publication bias and sensitivity analysis {#s2_9}
-----------------------------------------

The publication bias of the present meta-analysis was evaluated by funnel plot. The shape of the funnel plot was almost symmetrical. To test the stability of meta-analysis of sMICA/B and OS, we performed a sensitivity analysis by sequentially removing each eligible study. And the present meta-sensitivity analysis did not suggest an undue influence of any single study (Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}).

![Sensitivity analysis for soluble MICA/B to estimate the impact of individual studies on the results of the meta-analysis](oncotarget-08-96384-g004){#F4}

![Funnel plot of the bias for the analysis of the independent role of soluble MICA/B in OS in the different cancer types](oncotarget-08-96384-g005){#F5}

![Funnel plot of the bias for the analysis of the independent role of MICA/B in OS in the different cancer types](oncotarget-08-96384-g006){#F6}

DISCUSSION {#s3}
==========

To our our knowledge, the present meta-analysis is the first to comprehensively evaluate the association of immune effector molecule expression (MICA/B) and serum shedding immune effector molecules (sMICA/B) with prognosis in variable types of cancer. Our meta-analysis reviewed a total of 19 studies comprising 2,588 patients to determine the prognositic value of MICA/B and sMICA/B in 10 types of cancer. The overall pooled analysis of all types of cancer suggested that a high level of soluble MICA/B in serum was associated with poor OS, with no significant difference between cancer types. With regards to MICA/B expression as detected by IHC, high MICA/B expression level was associated with longer survival in cancers of the digestive system. However, no statistical significance was observed for MICA/B expression level when all types of cancer were considered. A high level of sMICA/B in serum had a negative prognostic effect on cancer patients. This finding suggested that shedding of NKG2D ligands by cancer cells enable these cells to evade the immune response by escaping detection by NK cells, γδ T cells and CD8+ T cells. Conversely, a high MICA/B expression was associated with a favorable outcome in cancers of the digestive system, supporting the notion that MICA/B is a critical ligand in immune cytotoxicity.

In serum, we observed that sMICA/B was an independent prognosis factor in cancer patients, with moderate heterogeneity. There were no significant differences in various type of cancers. Further, no significant heterogeneity was observed between sMICA and sMICB. Soluble MICA/B was a more reliable prognostic indicator compared with MICA/B cell surface expression, as the former is easier to detect and the results are less affected by individual estimates. To detect MICA/B expression in cacner cell surface, biopsies are necessary; however, cancerous sites are not always reachable. Moreover, not all patients with cancer are tolerant of biopsy. These factors decrease the feasibility of MICA/B detection by IHC. Therefore, soluble MICA/B in serum is more applicable in such situations. Furthermore, the interpretation of immunohistochemical staining is influenced by individual subjective factors, and results are more difficult to quantify. Overall, sMICA/B are more advantaged at cancer patient survival prognosis.

Unlike previous studies that have focused on cancer cell-centric prognosis biomarkers, such as microRNA, lncRNA, or relative progression proteins, the present meta-analysis focused on biomarkers associated with immune cell interaction \[[@R3], [@R35], [@R36]\]. Immune effector molecules MICA/B not only reflect a distinct underlying biology of the tumor, but they are also involved in innate immune activation and cancer immune tolerance \[[@R6]\]. Of the adoptive immunotherapeutic strategies, MICA/B or soluble MICA/B could be a reflection of a pre-existing immune con-texture and of the immune response to NK cell-, T cell-, and γδ T cell-based immunotherapy. Studies of cytokine-induced killer cell (CIK) therapy have reported that cancer patients with high MICA expression experienced a significantly greater survival benefit from CIK treatment \[[@R19], [@R21]\]. Therefore, prognostic markers MICA/B and sMICA/B may additionally serve as predictors of treatment outcomes in patients receiving immunotherapies.

No significant statistical difference was observed for the association between MICA/B expression and survival in all types of cancer. Subgroup analysis was conducted to explore the data further. We found that in respiratory and gynecologic malignant tumors, there was no evidence showing that MICA/B expression was associated with cancer outcome. However, the association between MICA/B expression and survival was significant for digestive system cancers (*P* = 0.002). The reasons underlying these inconsistent results may be manifold: it is speculated that in respiratory cancers and gynecologic malignant tumors, dedifferentiation results in the expression of MICA; however, in the absence of other pro-inflammatory signals, there was no infiltration of immune effector cells. Therefore, MICA expression had no influence on cancer survival in these cancer types. This has been observed in ovarian cancer, where high expression of MICA/B significantly correlated with lower degree of NK cells intra-epithelial infiltration \[[@R37]\]. In our studies, IHC data indicated a large proportion of cytoplasmic MICA/B expression instead of cell surface staining in lung cancers and gynecologic malignant tumors. This phenomenon was also reported by another two studies in clear cell renal cell carcinoma and breast cancer \[[@R23], [@R38]\]. However, a widely accepted theory is that MICA/B expressed on the cell surface, but not in the cytoplasm, interacts with NKG2D receptors on NK cells, γδ T cells, and T cells \[[@R39]\]. Alternatively, MICA/B expressed only within the cytoplasm results in the immune evasion by the cancer cell and limited survival for the patient, instead of cytoplasm.

There is no international unification measurement to determine levels of MICA/B, and MICA/B localisation is also not assessed in a standardized manner. In the included studies present in the present analysis, three major evaluation criteria were applied: the expression score was calculated by multiplying the intensity and positivity scores \[[@R27]\], or by adding these scores \[[@R19], [@R21]\], and the third criterion was evaluated according to staining intensity \[[@R33]\]. The heterogeneity associated with the evaluation criteria and cut-off point made the meta-analysis of MICA/B expression by IHC challenging.

Further, the current meta-analysis has several potential limitations: firstly, various factors such as heterogeneity in MICA/B expression IHC scoring strategies, cut-off points, and cancer stages restricted us from obtaining more comprehensive results. As the prognostic role of MICA/B seems to be substantially different according to cancer site, the overall pooled analysis of all types of cancer may have been highly dependent on the relative proportion of each specific type of cancer. Furthermore, in several studies, HR for outcome measures were derived from Kaplan--Meier survival curves when not provided by the original studies directly, and a few of the studies provided an inconsistent HR, 95% CI, and *P*-value. These inconsistencies were considered to have affected the level of evidence. These limitations mandate caution when interpreting the present results.

In conclusion, despite the limitations described above, the current meta-analysis provides evidence that sMICA/B levels serve as a reliable prognostic marker in various cancers. The expression levels of MICA/B on cancer cell surface were significantly associated with OS in patients with digestive system cancer. In addition to prognostic utility, an improved understanding of MICA/B in various cancers types should enable the development of more precise and effective immunotherapies.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

We conducted and reported this systematic review and meta-analysis in accordance with the PRISMA statement. We systematically searched PubMed, Embase, [Clinicaltrails.gov](http://Clinicaltrails.gov), and Cochrane Library(up to July 15, 2017), without language restrictions, for human studies of the prognostic significance of MICA/B and sMICA/B in cancer . The following keywords were used for the search: ("Prognosis" OR "Mortality" OR "Survival") AND ("MICA" OR "MICB" OR "MIC" OR "MICA/B" OR "MICA-B" OR "MHC class I-related chain A" OR "MHC class I chain related gene A protein" OR "MHC class I chain-related protein B" OR "MHC class I chain-related antigen B") AND ("Neoplasia" OR "Neoplasias" OR "Neoplasm" OR "Tumors" OR "Tumor" OR "Malignancy" OR "Malignancies" OR "Cancer" OR "Cancers" OR "Neoplasms"). We scrutinized the reference lists of the identified reports, reviews, meta-analyses, and other relevant publications to indentify additional pertinent studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Studies that met the following criteria were included in the meta-analysis: studies must have: (1) been published as original articles; (2) evaluated human subjects; (3) evaluated MICA, MICB or MICA/B in cancer surgical specimens using immunohistochemical method or any other method, or sMICA or sMICB in serum by ELISA and any other method; (4) reported association of high and low MICA/B expression with overall survival (OS); (5) reported association of high and low sMICA/B with OS; and (6) contained the minimum information necessary to estimate the effects (i.e., hazard ratio) and a corresponding measure of uncertainty (i.e., confidence interval, *P*-values, standard errors or variance). As an additional criterion, when a single population was reported in multiple reports, only the report with the most complete data was included to avoid duplication. Further, when a single report contained more than one unduplicated studies, all of the studies that met the inclusion criteria were included, and these studies were named by author and number. In this review, we additionally included studies that did not distinguish between MICA and MICB by immunohistochemistry, as the MICA and MICB locus encode the proteins of the same size with 83% similar amino acid sequence, and no distinct functions relating to cancer immune response have been found \[[@R40]\]. The eligibility of each study was assessed independently by two investigators (YJ.Z and NF.C). We excluded studies that were not published as full reports, such as conference abstracts and letters to editors, as well as studies that did not report sufficient data for the estimation of survival rates.

Assessment of risk of bias {#s4_3}
--------------------------

We used the NOS to assess the risk of bias \[[@R41]\]. The NOS evaluates a high quality study in three domains: selection of participants, comparability of study groups, and the ascertainment of outcomes of interest. We considered studies that received a score of seven or more than that as low risk of bias, and those that scored less than seven as high risk of bias. This cut-off point was chosen according to the distribution of relative quality scores of all included studies.

Data extraction {#s4_4}
---------------

Two investigators (YJ.Z and NF.C) independently summarized the studies meeting the inclusion criteria and performed data extraction using a predefined form, recording: author, year of publication, MICA or MICB or sMICA or sMICB, sample size, cancer type, median follow-up time, country, scoring protocols to identify MICA/B expression, cut-off point to identify sMICA/B, expression (High: Low), method of study, outcome of univariate and/or multivariate analysis (including *P*-values, hazard ratios \[HR\], and 95% confidence intervals \[CI\]).

Indices {#s4_5}
-------

The endpoint used in this meta-analysis was OS. For MICA/B, study-defined binary variables indicating either the presence (versus absence), positive (versus negative), or high (versus low) expression were used and described as "high" or "low" MICA/B expression. For sMICA/B in serum, study-defined binary variables indicating either more (versus less) or high (versus low) were also described as "high " or "low" level.

Statistical analyses {#s4_6}
--------------------

The present meta-analysis and statistical analyses were using Revman software (version 5.3; Cochrane Collaboration, Oxford, United Kingdom). HR and its 95% CI were used to estimate the association between MICA/B and prognosis. For sensitivity analysis, we used Stata software (version 14.2;STATA Corp., College Station, TX, USA). If results of both univariate and multivariate Cox regression analyses were reported, we used estimates from the multivariate Cox regression model for a more direct estimate of the effect of MICA after controlling for potential confounding variables. If a direct reported of HR and 95% CI were not available, survival data from Kaplan-Meier curves were read using Engauge Digitizer version 9.7 (<http://digitizer.sourceforge.net/>) as described previously. The calculation method for HR was based on Tierney\'s protocol \[[@R42], [@R43]\]. This work was performed by two independent reviewers (YJ.Z and NF.C) to reduce inaccuracy in the extracted survival rates.

We assessed heterogeneity between studies with the I^2^ statistic as a measure of the proportion of total variation in estimates due to heterogeneity, where I^2^ values of 25%, 50%, and 75% corresponded to cut-off points for low, moderate, and high degrees of heterogeneity. Subgroup analyses were carried out to investigate potential sources of heterogeneity. Sensitive analysis conducted to assess whether conclusions were sensitive to restricted studies. Subgroups were defined according to different types of cancer, sample sizes, multivariate correction, and whether MICA or MICB were assessed together or individually. Tests for the effects of subgroup interaction were performed.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
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ADAM

:   A disintegrin and metalloproteinase

CI

:   Confidence interval

HR

:   Hazard ratio

MHC

:   Major histocompatibility complex

MICA

:   MHC class I polypeptide-related sequence A

MICB

:   MHC class I polypeptide-related sequence B

NKG2D

:   Natural killer group 2D

OS

:   Overall survival

OSCC

:   Oral squamous cell carcinoma

sMICA

:   Soluble MHC class I polypeptide-related sequence A

sMICB

:   Soluble MHC class I polypeptide-related sequence B

IHC

:   Immunohistochemistry
